Read the latest WaveData articles, or search through our archive.

Follow us on LinkedIn to keep up to date with WaveData news, articles, insights and analysis

Please use complete words when searching…

Does competition drive lower prices?

Does competition drive lower prices?

Wavedata looked at the average prices of generic products sold to pharmacies and dispensing doctors between August and October 2023 and compared this with the number of price list offers for the same products in the same time period.

read more
Typical and atypical long term pricing after loss of exclusivity

Typical and atypical long term pricing after loss of exclusivity

The first generic versions of Zonisamide Caps 25mg 14 were launched after loss of exclusivity in November 2015. However, in the run-up to this, the prices being offered to pharmacists and dispensing doctors for the brand declined from about £8.00 to about £7.40. This may be because of parallel import competition against the UK brand.

read more
Eplerenone Tabs unstable long term pricing

Eplerenone Tabs unstable long term pricing

Eplerenone Tabs were launched in September 2014 after the loss of exclusivity of Pfizer’s Inspra brand. Eplerenone is one of those products which is subject to regular price bounces, concessions and shortages. Each of the two packs has experienced three price bounces and three concessions over the last 10 years.

read more
Are concessions and shortages caused by the DHSC?

Are concessions and shortages caused by the DHSC?

It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for all the products in the English drug tariff over the last 10 years.

read more
What’s the future for my brand post loss of exclusivity (LOE)?

What’s the future for my brand post loss of exclusivity (LOE)?

Charles Joynson, WaveData MD, puts a spotlight on Lustral Tabs as we explore the product lifecycle post LOE.

Before generics were launched in November 2005 there was a high degree of similarity between the price of the UK and PI (parallel import) packs of Lustral Tabs 50mg 28. However, as soon as generics were launched the market became much more erratic.

read more
Charles Joynson, WaveData MD, investigates Mebeverine Suspension S/F 50mg/5ml 300ml, DHSC Price Concessions and Pharmacy Profits.

Charles Joynson, WaveData MD, investigates Mebeverine Suspension S/F 50mg/5ml 300ml, DHSC Price Concessions and Pharmacy Profits.

At first we struggled to understand why this product had been added to the list of DHSC Concessions in July. Actually it had the highest concession price at £214.96, but the market price had remained high as had the reimbursement price. However it was only when we began to think about pharmacy profitability that the penny dropped.

read more
Increases in the prices pharmacists have to pay for Atorvastatin have been much in the news recently. However, are other statins also increasing in price?

Increases in the prices pharmacists have to pay for Atorvastatin have been much in the news recently. However, are other statins also increasing in price?

Charles Joynson, WaveData MD decided to investigate further.
Firstly all packs of Atorvastatin Tabs have seen price increases in recent weeks except the 60mg 28 and the 30mg 28 packs. It may be that they are used less frequently and the pressure on supply is less intense. The four main 28 Tablet packs of Rosuvastatin have all seen price increases, but Simvastatin and Pravastatin have not.

read more
Morphine Sulphate Solution for Injection Amps 30mg/1ml 10 Long Term UK Market Price Trend

Morphine Sulphate Solution for Injection Amps 30mg/1ml 10 Long Term UK Market Price Trend

Since Feb 2022 the market price for this Category C product has risen from around £9 to over £20. However, for the eight years prior the prices were stable and the drug tariff remained on or just above the average UK market price. Despite an increase in reimbursement at the end of 2017 there was very little profit to be squeezed from this critical care pain killer.

read more
Long Term UK Market Price Trend of Gentamicin Ear / Eye Drops 0.3% 10ml

Long Term UK Market Price Trend of Gentamicin Ear / Eye Drops 0.3% 10ml

Until May 2021 this Category C product had stable pricing and very little profit potential. The average market price between July 2013 and April 2021 was £2.08 and the tariff £2.39, giving pharmacies £0.31, and manufacturers and wholesalers even less. In May 2021 prices rose substantially and since then the average tariff has been £24.10 and the average market price £12.30, leaving a healthy profit of £11.80 for pharmacies and the rest of the supply chain.

read more
WaveData Case Study – Bespoke Reports: Generics Market Assessment

WaveData Case Study – Bespoke Reports: Generics Market Assessment

Client X is launching a new generic product into the UK market, they were looking for data to assess market potential, support their forecasting and feed into the commercial strategy.
Our Customer Success Manager and Data Team worked closely with the Client’s Portfolio Manager and Commercial Manager to ensure we provided the right data for their project needs.

read more
WaveData Analysis | Long Term Pricing Trends | Aripiprazole Tabs 5mg 28

WaveData Analysis | Long Term Pricing Trends | Aripiprazole Tabs 5mg 28

This product was launched in December 2014 and has had a reasonably stable price there after. The average price came down very quickly, reaching stability by mid 2016. However, since then this product has experienced a couple of price bounces where the average price rose unexpectedly, concessions had to be granted and increases in the drug tariff followed. Monitoring the price and setting a low watch point could help us identify a future bounce.

read more
How serious is the issue of shortages in the UK Pharma market asks Charles Joynson?

How serious is the issue of shortages in the UK Pharma market asks Charles Joynson?

There are two primary ways in which shortages are flagged for pharmacists and dispensers. The first is the granting of a concession for generic products and the second is the product’s addition to the NHS’ serious shortage protocols (SSP) list. These have both been operating for some years and the number of products in each has been growing. The number of generic concessions granted each month has risen to nearly 200 whilst the number of SSPs is approaching 20.

This is the situation at present….. However, there is a threat that shortages might get much worse. This is driven by the voluntary scheme for branded medicines pricing and access (VPAS) and by the rebates paid back by manufacturers of branded and branded generic drugs as part of this scheme. Previous analyses by Wavedata have suggested that 22% of branded medicines and 49% of branded generics do not have sufficient profitability to survive the high rebates and are likely to be removed from sale in the UK.

read more